Preparation "Trifas": instructions for use, analogues and reviews

Pathological conditions in essential hypertension and heart failure are accompanied by swelling of soft tissues and internal organs, which are dangerous to humans. To remove excess fluid from the body use diuretics, which increase the volume of urine and remove minerals. One of such diuretics is the medicine "Trifas".

Description of the preparation

In the preparation there is an active component torasemide, the basis of which is sulfamonlantranilic acid. This substance is related to saluretics, which exert a retarding effect on the reabsorption of chloride and sodium ions in the kidneys.

Form of issue

There are several modifications of the preparation "Trifas", the instruction for the use of a solid and liquid dosage form is different. In each of them, the physical and chemical properties of tablets and solutions are described.

Tablet forms of the drug are issued under the trade name "Trifas 10" with a dosage of torasemide 10 mg and "Trifas COR" with a dose of torasemide 5 mg. The description states that the white tablets have a circular shape with a risk for dividing on one side at a higher dosage.

The liquid form of the Trifas preparation is described by the instruction as a solution for injections in a dosage of torasemide 10 mg per 2 ml and 20 mg per 4 ml, a solution for infusions at a dosage of 200 mg per 20 ml of liquid. According to the description, these are colorless transparent solutions, in which there is practically no inclusion of particles.

Description of the composition of tablets

For one tablet of the "Trifas" preparation, the instruction describes the formulation: the content of the active component of torasemide in an amount of 10 mg or 5 mg, and there are also inactive substances that maintain the structure of the tablet, its solubility and safety for the specified period. These include milk sugar, corn starch, magnesium stearate and anhydrous aerosil.

Description of the composition of solutions

In ampoules with 2 ml of solution for injection sodium torasemide is included in the amount of 10,631 mg, which is equivalent to 10 mg of torasemide.

In ampoules with 4 ml of solution for injection contains sodium torasemide in the amount of 21,262 mg, which is equivalent to 20 mg of torasemide.

In ampoules with 20 ml of solution for infusions, sodium torasemide is included in the amount of 212.62 mg, which is equivalent to 200 mg of torasemide.

In addition to the active substance, a small amount of sodium hydroxide, polyethylene glycol 400, trometamol is dissolved in injection water.

Mechanism of action

On the preparation "Trifas 10", the instruction for use contains a description of the binding of the incoming torasemide in the lumen of the nephron with the Na-K-Cl-cotransporter, which is a protein present in the surface of the cell, which suppresses transport of the K ⁺ , Na ⁺ ion Cl ^- through the channel lumen.

The diuretic effect of the tablets develops after 3 hours and lasts about 12 hours. The drug works even when there is no effect from other diuretics, for example, thiazide. Reducing the overall peripheral resistance of the vessels by balancing the equilibrium of electrolytes and the binding of free calcium ions in the smooth muscle of the arterial wall, the medication lowers blood pressure.

What the drug treats

Tablets of the preparation "Trifas" were used for application in essential hypertension, for the treatment and prevention of the onset of edematous conditions or exudates accompanying heart failure.

The solution for intravenous administration is administered with pulmonary edema, and infusion solutions are used in patients with reduced renal function, when the creatinine clearance rate is less than 20 ml per minute.

How to take pills

With essential hypertension, the "Trifas" preparation is used, the instruction for the use of the tablet is recommended to be divided into four parts and begin treatment with a daily dosage of 2.5 mg of torasemide. Decrease in pressure does not occur immediately, but within the first week, the maximum effect occurs no later than 12 weeks. In the absence of an antihypertensive effect, the daily dose of the "Trifas" drug is increased three-three months later, the instruction for the use of the tablet advises to be divided in half, each of these halves contains 5 mg of torasemide.

With arterial hypertension, when the diastolic pressure exceeds 115 mmHg and the renal function is limited, an additional antihypertensive effect may occur.

When swelling or swelling a day use 5 mg of torasemide or ½ part of the tablet "Trifas 10", the instruction for use has information on the need to increase the dosage to 20 mg of torasemide in the absence of effect, which corresponds to two tablets of the drug. Drink medicines in the morning, without violating the integrity and washing down with liquid. The intake of food does not affect the assimilation of tablets, and the duration of therapy is associated with the nature and course of the disease.

How to use a solution for injections

For the treatment of adults with Trifas, the instructions for use include recommendations on the use of a single daily dosage of 2 ml, which contains 10 mg of torasemide. If necessary, the daily dosage is increased to 4 ml, which corresponds to 20 mg of the active ingredient. If the effect is insufficient, a daily dosage of 8 ml, equivalent to 40 mg of torasemide, but not more than 3 days, is used.

The state of acute pulmonary edema is eliminated by administering 4 ml of an ampoule solution with a dosage of 10 mg of torasemide. With insufficient efficiency, after half an hour, a repeated injection of 4 ml of the drug solution is carried out. It is undesirable to exceed the dose of 100 mg of torasemide per day, which corresponds to 20 ml of the "Trifas" solution.

How to use a solution for infusions

The instructions describe the use of an infusion set for adults. The condition of the patient with insufficient kidneys determines the dose of the drug. The application starts with a daily dosage of 5 ml, which contains 50 mg of torasemide. If this dose does not increase urine output, it is increased to 10 ml. The maximum increase to 20 ml of the infusion solution of the preparation "Trifas 200", which contains 200 mg of torasemide, is permissible. Repeated intravenous administration is carried out after 1 hour, using a perfusor to establish infusion rate of 0.4 ml per minute. For convenience, 1 ampoule diluted 500, 250, 125 or 30 ml of 0.9% sodium chloride solution or 5% glucose solution. Such a mixture must be used immediately, the remainder poured out.

Intravenous treatment should not exceed one week, it is desirable as soon as possible to switch to taking tablets.

Application Features

Long-term use of the preparation "Trifas" instructions for use characterizes as a condition requiring regular monitoring of the balance of electrolytes, especially potassium ions in the blood serum. Glucose, creatinine, uric acid and fats - all these indicators require measurement in order to timely reveal the development of diabetes mellitus. During the treatment you need to monitor the patient's blood.

In pregnancy and lactation, it is best not to use the drug, since there is no reliable data on the safety of torasemide for the child.

The action of the drug may reduce the activity of a person while driving a car and other mechanisms requiring attention. Do not combine it with alcoholic beverages.

To whom is contraindicated treatment

Not everyone can take the drug "Trifas", the instruction for use lists the conditions under which therapy is contraindicated.

Do not use:

• With increased sensitivity to torasemide and its derivatives in the past;
• With hypotension;
• With renal insufficiency;
• With anuria;
• With a serious disruption of the liver, including a coma or a premo;
• With a decrease in the volume of moving blood;
• With a reduced content of sodium and potassium in the blood;
• With impaired urination due to enlarged prostate gland;
• With excessive deposition of oxalates in the joints;
• With increased excitability and conduction of the heart muscle;
• With disturbed acid-base balance;
• With anemia and a small number of platelets;
• At disturbances of work of kidneys;
• In children under 12 years of age.

Unwanted consequences

The list of side effects includes an instruction for the preparation of "Trifas". Patients' opinions indicate the frequency of certain unintended consequences.

The medication acts on the cardiovascular system in violation of the water-electrolyte balance, leading to hypovolemia, hypokalemia, hyponatremia, alkalosis, headache, dizziness, fatigue, muscle cramps, severe urination to hypotension, clouding of consciousness, thrombosis, cardiac and cerebral Ischemia, heart rhythm disorder, angina pectoris, acute myocardial infarction, fainting.

On the digestive system, torasemide acts with the manifestation of constipation, lack of food, nausea, vomiting, pain in the stomach, diarrhea.

Patients with urinary disorders associated with prostatic hypertrophy, with intensive urine formation, feel its delay and excessive stretching of the walls of the bladder.

The drug affects the metabolic processes, in violation of which in the blood plasma uric acid, glucose, triglycerides and cholesterol begin to linger, which increases their concentration.

When exposed to the liver, the content of its enzymes, for example, gamma-glutamyl-transpeptidase, can increase.

Under the action of the drug in the blood, the number of platelets, erythrocyte and leukocyte cells decreases.

Undesirable effects from the action of torasemide are associated with an increased sensitivity of the organism, manifested by itching, exanthema, photosensitivity. Sometimes the state of anaphylactic shock can develop from the administration of the solution intravenously, which requires an urgent reaction.

Analogues

The manufacturer of the original preparation "Trifas" is the German company "Berlin-Chemie AG Menaryini Group", which produces a liquid and solid form of this medication. On the pharmaceutical market in Russia, you can find generic drugs that contain torasemide. All of them have diuretic properties, the same mechanism of action and similar side reactions caused by the active substance.

The drug "Trifas" analogs are produced both in the form of tablets for oral administration, and in the form of solutions for injections and infusions.

One of the synonyms is the drug "Diver", produced by the Croatian company Pliva Hrvatskaya doo. The drug is given in tablets with a dosage of 5 and 10 mg of torasemide.

The German analogue is the drug "Torasemid Sandoz", manufactured by the company "Salutas Pharma GmbH". Produced in the form of tablets with torasemide content of 200 mg, 100 mg, 50 mg, 20 mg, 10 mg, 5 mg and 2.5 mg.

Tablets "Britamor" with prolonged action are produced by the Spanish company "Ferrer international SA". This analog contains 5 mg and 10 mg of torasemide.

The drug "Toradiv" of the Ukrainian enterprise "Farmeks Group Ltd" is manufactured in tablets of 5 mg, 10 mg torasemide and in the form of a solution for injection of 5 mg torasemide per 2 ml or 4 mg liquid.

Reviews

Useful information for patients contains the instructions for use on the preparation "Trifas". Feedback from patients taking this drug, indicate the effectiveness of the drug in swelling. Daily use of torasemide helps reduce the effect of excess fluid on the myocardium in heart disease. With proper therapy, patients regularly take tests to assess the effect of the drug on the body.

On the treatment of the drug "Trifas 10", the instruction reviews describe more positive than negative statements. Undesirable actions are extremely rare, but many patients, after reading the section "Adverse Reactions", are afraid to take the drug. And in vain, side effects do not necessarily have to appear, but torasemide will help to remove swelling, remove excess fluid and reduce blood pressure. Reducing the amount of fluid will normalize all vital processes, water-salt balance and improve the patient's condition in heart failure.

There are reviews about the ineffectiveness of the drug in the puffiness of the body. In this case, the attending physician should select the appropriate treatment with similar medications, but not containing torasemide.